Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, 158 Shangtang Road, Hangzhou, 310014, Zhejiang, China.
Key Laboratory of Endocrine Gland Diseases of Zhejiang Province, 158 Shangtang Road, Hangzhou, 310014, China.
J Exp Clin Cancer Res. 2023 Mar 14;42(1):62. doi: 10.1186/s13046-023-02635-y.
Non-protein target drugs, especially RNA-based gene therapies for treating hereditary diseases, have been recognized worldwide. As cancer is an insurmountable challenge, no miracle drug is currently available. With the advancements in the field of biopharmaceuticals, research on cancer therapy has gradually focused on non-protein target-targeted drugs, especially RNA therapeutics, including oligonucleotide drugs and mRNA vaccines. This review mainly summarizes the clinical research progress in RNA therapeutics and highlights that appropriate target selection and optimized delivery vehicles are key factors in increasing the effectiveness of cancer treatment in vivo.
非蛋白靶标药物,特别是基于 RNA 的遗传性疾病基因治疗药物,已在全球范围内得到认可。由于癌症是一个难以逾越的挑战,目前尚无特效药物。随着生物制药领域的进步,癌症治疗的研究逐渐集中在非蛋白靶标药物上,特别是 RNA 疗法,包括寡核苷酸药物和 mRNA 疫苗。本文主要综述了 RNA 疗法的临床研究进展,并强调了适当的靶标选择和优化的递送载体是提高体内癌症治疗效果的关键因素。